Logo image of ALBIO.PA

BIOSYNEX (ALBIO.PA) Stock Price, Quote, News and Overview

EPA:ALBIO - Euronext Paris - Matif - FR0011005933 - Common Stock - Currency: EUR

1.245  +0.05 (+3.75%)

ALBIO.PA Quote, Performance and Key Statistics

BIOSYNEX

EPA:ALBIO (6/18/2025, 7:00:00 PM)

1.245

+0.05 (+3.75%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High6.92
52 Week Low1.05
Market Cap23.34M
Shares18.75M
Float7.78M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE2.63
Earnings (Next)N/A N/A
IPO03-21 2011-03-21


ALBIO.PA short term performance overview.The bars show the price performance of ALBIO.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15

ALBIO.PA long term performance overview.The bars show the price performance of ALBIO.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALBIO.PA is 1.245 EUR. In the past month the price decreased by -4.96%. In the past year, price decreased by -62.67%.

BIOSYNEX / ALBIO Daily stock chart

ALBIO.PA Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABL.DE ABBOTT LABORATORIES 27.79 200.67B
1ISRG.MI INTUITIVE SURGICAL INC 67.85 161.49B
IUI1.DE INTUITIVE SURGICAL INC 67.09 159.68B
BSX.DE BOSTON SCIENTIFIC CORP 37.53 130.49B
2M6.DE MEDTRONIC PLC 15.66 96.00B
SHL.DE SIEMENS HEALTHINEERS AG 19.89 50.71B
BOX.DE BECTON DICKINSON AND CO 12.08 42.38B
EWL.DE EDWARDS LIFESCIENCES CORP 28.38 37.62B
DC4.DE DEXCOM INC 49.43 27.71B
1PHIA.MI KONINKLIJKE PHILIPS NV 14.18 18.39B
PHI1.DE KONINKLIJKE PHILIPS NV 14.08 18.27B
PHIA.AS KONINKLIJKE PHILIPS NV 13.87 17.99B

About ALBIO.PA

Company Profile

ALBIO logo image Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 521 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

Company Info

BIOSYNEX

22 Boulevard Sebastien Brant

Illkirch-Graffenstaden GRAND EST FR

Employees: 521

ALBIO Company Website

ALBIO Investor Relations

Phone: 33388787887

BIOSYNEX / ALBIO.PA FAQ

What is the stock price of BIOSYNEX today?

The current stock price of ALBIO.PA is 1.245 EUR. The price increased by 3.75% in the last trading session.


What is the ticker symbol for BIOSYNEX stock?

The exchange symbol of BIOSYNEX is ALBIO and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALBIO.PA stock listed?

ALBIO.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for BIOSYNEX stock?

9 analysts have analysed ALBIO.PA and the average price target is 12.85 EUR. This implies a price increase of 932.29% is expected in the next year compared to the current price of 1.245. Check the BIOSYNEX stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIOSYNEX worth?

BIOSYNEX (ALBIO.PA) has a market capitalization of 23.34M EUR. This makes ALBIO.PA a Nano Cap stock.


How many employees does BIOSYNEX have?

BIOSYNEX (ALBIO.PA) currently has 521 employees.


What are the support and resistance levels for BIOSYNEX (ALBIO.PA) stock?

BIOSYNEX (ALBIO.PA) has a resistance level at 1.26. Check the full technical report for a detailed analysis of ALBIO.PA support and resistance levels.


Is BIOSYNEX (ALBIO.PA) expected to grow?

The Revenue of BIOSYNEX (ALBIO.PA) is expected to grow by 15.05% in the next year. Check the estimates tab for more information on the ALBIO.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOSYNEX (ALBIO.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOSYNEX (ALBIO.PA) stock pay dividends?

ALBIO.PA does not pay a dividend.


What is the Price/Earnings (PE) ratio of BIOSYNEX (ALBIO.PA)?

BIOSYNEX (ALBIO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.37).


ALBIO.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALBIO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA. ALBIO.PA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALBIO.PA Financial Highlights

Over the last trailing twelve months ALBIO.PA reported a non-GAAP Earnings per Share(EPS) of -3.37. The EPS decreased by -12.27% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -22.24%
ROE -53.75%
Debt/Equity 0.19
Chartmill High Growth Momentum
EPS Q2Q%-22.69%
Sales Q2Q%-5.76%
EPS 1Y (TTM)-12.27%
Revenue 1Y (TTM)8.76%

ALBIO.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ALBIO.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 475% and a revenue growth 15.05% for ALBIO.PA


Ownership
Inst Owners0.46%
Ins Owners5.7%
Short Float %N/A
Short RatioN/A
Analysts
Analysts86.67
Price Target12.85 (932.13%)
EPS Next Y475%
Revenue Next Year15.05%